Ignite Creation Date:
2025-12-24 @ 7:59 PM
Ignite Modification Date:
2025-12-29 @ 9:25 PM
Study NCT ID:
NCT04191304
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-11-26
First Post:
2019-11-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-07-20
Start Date Type:
ACTUAL
Primary Completion Date:
2025-05-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2026-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2019-11-20
First Submit QC Date:
None
Study First Post Date:
2019-12-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-25
Last Update Post Date:
2025-11-26
Last Update Post Date Type:
ESTIMATED